Perceptive Advisors - Q4 2015 holdings

$1.35 Billion is the total value of Perceptive Advisors's 155 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was 100.0% .

 Value Shares↓ Weighting
CNAT ExitCONATUS PHARMACEUTICALS INC$0-850
-100.0%
0.00%
XBI ExitSTREETTRACKS SPDR BIOTEC ETFcall$0-200
-100.0%
0.00%
VRX ExitVALEANT PHARMACEUTICALS INTERNATIONAL INcall$0-200
-100.0%
-0.00%
NUVA ExitNUVASIVE INC$0-504
-100.0%
-0.00%
JNP ExitJUNIPER PHARMACEUTICALS INC$0-3,472
-100.0%
-0.00%
AMAG ExitAMAG PHARMACEUTICALS INC$0-5,808
-100.0%
-0.01%
DVCR ExitDIVERSICARE HEALTHCARE SVCS$0-24,674
-100.0%
-0.01%
REPH ExitRECRO PHARMA INC$0-24,126
-100.0%
-0.01%
WCG ExitWELLCARE HEALTH PLANS INC$0-4,378
-100.0%
-0.02%
CNCE ExitCONCERT PHARMACEUTICALS INC$0-20,758
-100.0%
-0.02%
HCA ExitHCA HOLDINGS INC$0-5,126
-100.0%
-0.02%
CAH ExitCARDINAL HEALTH INC$0-5,148
-100.0%
-0.02%
ExitANTHEM INC$0-2,872
-100.0%
-0.02%
EW ExitEDWARDS LIFESCIENCES CORP$0-3,000
-100.0%
-0.02%
ExitADDUS HOMECARE CORP$0-15,202
-100.0%
-0.02%
INCR ExitINC RESH HLDGS INCcl a$0-14,522
-100.0%
-0.02%
AET ExitAETNA INC NEW$0-5,172
-100.0%
-0.02%
QTNTW ExitQUOTIENT LTD*w exp 10/30/201$0-262,502
-100.0%
-0.04%
TBT ExitPROSHARES TR$0-24,000
-100.0%
-0.04%
SNSS ExitSUNESIS PHARMACEUTICALS INC$0-1,400,000
-100.0%
-0.04%
XNCR ExitXENCOR INCput$0-100,000
-100.0%
-0.05%
ACST ExitACASTI PHARMA INC$0-4,731,200
-100.0%
-0.05%
IRWD ExitIRONWOOD PHARMACEUTICALS INC$0-172,458
-100.0%
-0.07%
BCLI ExitBRAINSTORM CELL THERAPEUTICS$0-800,000
-100.0%
-0.07%
SGYPQ ExitSYNERGY PHARMACEUTICALS DEL$0-452,000
-100.0%
-0.10%
UUP ExitPOWERSHS DB US DOLLAR INDEXdoll indx bull$0-110,000
-100.0%
-0.11%
BCRX ExitBIOCRYST PHARMACEUTICALS$0-247,490
-100.0%
-0.11%
RPRX ExitREPROS THERAPEUTICS INC$0-440,000
-100.0%
-0.13%
PTCT ExitPTC THERAPEUTICS INCcall$0-200,000
-100.0%
-0.21%
RGEN ExitREPLIGEN CORPput$0-200,000
-100.0%
-0.22%
CYAD ExitCELYAD SAadr$0-150,000
-100.0%
-0.25%
STJ ExitST JUDE MED INC$0-103,040
-100.0%
-0.26%
RLYP ExitRELYPSA INCput$0-500,000
-100.0%
-0.37%
THOR ExitTHORATEC CORP$0-172,000
-100.0%
-0.44%
RLYP ExitRELYPSA INCcall$0-600,000
-100.0%
-0.44%
THOR ExitTHORATEC CORPcall$0-200,000
-100.0%
-0.51%
SHPG ExitSHIRE PLCsponsored adr$0-82,000
-100.0%
-0.67%
GILD ExitGILEAD SCIENCES INCput$0-200,000
-100.0%
-0.78%
NVO ExitNOVO-NORDISK A/S-SPONS ADRput$0-400,000
-100.0%
-0.87%
SSO ExitPROSHARES ULTRA S & P500put$0-400,000
-100.0%
-0.89%
CEMP ExitCEMPRA INC$0-1,165,000
-100.0%
-1.30%
XBI ExitSTREETTRACKS SPDR BIOTEC ETFput$0-550,000
-100.0%
-1.37%
RLYP ExitRELYPSA INC$0-1,975,884
-100.0%
-1.46%
IWM ExitISHARES RUSSELL 2000put$0-400,000
-100.0%
-1.74%
PTCT ExitPTC THERAPEUTICS INCput$0-2,010,000
-100.0%
-2.14%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2016-02-16
Signatures

The EDGAR filing(s) were signed by:

About Perceptive Advisors

Perceptive Advisors is a New York-based hedge fund that specializes in healthcare investments. The company was founded in 1999 by Joseph Edelman, who serves as the CEO and Chief Investment Officer. Since its inception, Perceptive Advisors has become one of the most successful healthcare-focused hedge funds in the world, with over $5 billion in assets under management.

The company's investment strategy is based on a deep understanding of the healthcare industry and a focus on identifying promising companies with innovative products and technologies. Perceptive Advisors invests in a wide range of healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services.

One of the key factors behind Perceptive Advisors' success is its team of experienced professionals. In addition to Joseph Edelman, the company's leadership team includes Adam Stone, the COO, and Jeremy Goldberg, the Chief Scientific Officer. The team also includes a group of highly skilled analysts and researchers who are experts in their respective fields.

Perceptive Advisors has a strong track record of generating high returns for its investors. However, it is important to note that investing in hedge funds carries significant risks, and investors should carefully consider their investment objectives and risk tolerance before investing. As with any investment, it is important to conduct thorough research and seek the advice of a qualified financial advisor before making any investment decisions.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
NEUROCRINE BIOSCIENCES SHARES42Q3 202315.7%
AMICUS THERAPEUTICS SHARES39Q3 202314.0%
ALDEYRA THERAPEUTICS SHARES35Q3 20233.3%
QUOTIENT TECHNOLOGY INC34Q3 20222.7%
GLOBAL BLOOD THERAPEUTICS SHARES29Q3 20229.3%
ADMA BIOLOGICS SHARES29Q3 20231.4%
RETROPHIN SHARES28Q3 20205.5%
DBV TECHNOLOGIES SA-SPON ADR28Q3 20211.8%
VBI VACCINES SHARES27Q1 20232.8%
IOVANCE BIOTHERAPEUTICS INC26Q3 20239.1%

View Perceptive Advisors's complete holdings history.

Latest significant ownerships (13-D/G)
Perceptive Advisors Q4 2015 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
CHEMBIO DIAGNOSTICS, INC.Sold outMay 04, 202300.0%
VBI Vaccines Inc/BCApril 07, 202343,509,55316.7%
Landos Biopharma, Inc.March 30, 202314,869,91547.7%
REATA PHARMACEUTICALS INCMarch 07, 20232,083,7996.5%
AGILE THERAPEUTICS INCSold outFebruary 14, 202300.0%
ALBIREO PHARMA, INC.February 14, 20231,757,1608.5%
BELLUS Health Inc.February 14, 20238,891,0277.1%
CinCor Pharma, Inc.February 14, 20232,576,3255.9%
Coherus BioSciences, Inc.Sold outFebruary 14, 202300.0%
CONCERT PHARMACEUTICALS, INC.February 14, 20231,800,0003.6%

View Perceptive Advisors's complete significant-ownership history.

Latest filings
TypeFiled
SC 13D/A2024-05-01
SC 13D/A2024-04-17
SC 13D/A2024-04-17
42024-04-15
SC 13G/A2024-04-15
SC 13G2024-04-15
SC 13D/A2024-04-10
42024-04-08
42024-04-03
SC 13D/A2024-04-03

View Perceptive Advisors's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported total value is incorrect (1353145000.0 != 1351627000.0)

Export Perceptive Advisors's holdings